Product image of Granisetron Fresenius Kabi (Granisetron Hydrochloride) supplied by GNH India

Granisetron Fresenius Kabi

Active Ingredient:
Granisetron Hydrochloride
Origin:
EU

Granisetron Fresenius Kabi (Granisetron Hydrochloride)

Granisetron Fresenius Kabi is an intravenous formulation containing the active ingredient granisetron hydrochloride. It is a prescription‑only 5‑HT3 receptor antagonist marketed in the European Union. The product is used to prevent nausea and vomiting associated with chemotherapy and surgery, acting by selectively blocking serotonin receptors in the central nervous system.

Manufacturer / TM Owner

Fresenius Kabi Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings. It is commonly employed in oncology and peri‑operative care.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV)
  • Prevention of postoperative nausea and vomiting (PONV)
  • Use as part of anti‑emetic prophylaxis protocols
  • Administration before highly emetogenic chemotherapy regimens
  • Use in patients at high risk for nausea and vomiting due to surgical procedures

Side Effects

Granisetron Fresenius Kabi may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common

  • Headache
  • Constipation
  • Fatigue
  • Dizziness
  • Injection site discomfort

Serious

  • Severe allergic reaction (anaphylaxis)
  • Cardiac arrhythmias or QT prolongation

Precautions & Warnings

When prescribing Granisetron Fresenius Kabi, clinicians should consider several safety aspects to minimize risk.

  • Assess patient history for cardiac disease or electrolyte abnormalities
  • Use caution in patients with prolonged QT interval
  • Monitor for signs of hypersensitivity during and after infusion
  • Adjust dose in patients with hepatic impairment as recommended
  • Avoid use in patients with known hypersensitivity to granisetron or related compounds
  • Evaluate pregnancy and lactation status; safety data are limited

Avoid Interactions

Granisetron Fresenius Kabi can interact with other medications, influencing its efficacy or safety profile.

Avoid

  • Other 5‑HT3 antagonists used concurrently
  • Drugs known to significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics)

Use with caution

  • CYP3A4 inhibitors or inducers that may affect granisetron metabolism
  • Anticholinergic agents that could exacerbate constipation
  • Opioids, as they may increase the risk of constipation
  • Medications that also affect cardiac conduction

Frequently Asked Questions

Granisetron Fresenius Kabi is an intravenous prescription drug that contains granisetron hydrochloride, a selective 5‑HT3 receptor antagonist used to prevent nausea and vomiting.

It is commonly prescribed to prevent chemotherapy‑induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

Granisetron blocks serotonin (5‑HT3) receptors in the central nervous system and gastrointestinal tract, interrupting the signaling pathway that triggers vomiting.

No, it is a prescription‑only medication and must be prescribed by a qualified healthcare professional.

Yes, constipation is listed as a common side effect of Granisetron Fresenius Kabi.

Serious risks include severe allergic reactions such as anaphylaxis and cardiac arrhythmias, including QT interval prolongation.

Patients with known cardiac disease or a prolonged QT interval should use Granisetron with caution and be closely monitored.

Yes, avoid combining it with other 5‑HT3 antagonists and drugs that significantly prolong the QT interval. Use caution with CYP3A4 modulators, anticholinergics, opioids, and other cardiac‑affecting medications.

Safety data for use during pregnancy are limited, and the medication should only be used if the potential benefit justifies the potential risk to the fetus.

It is administered intravenously, typically as an infusion before chemotherapy or surgery, according to the prescribing information.

Patients should be monitored for signs of allergic reaction, cardiac rhythm changes, and any new or worsening side effects.

Use in pediatric patients should follow specific dosing guidelines and be determined by a pediatric specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT